{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005235","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.282488+00:00","generated_at":"2026-05-17T16:29:28.887230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Edesa Biotech reports Q3 net loss of $1.7M; advances EB06 manufacturing for vitiligo Phase 2","bullets":["Net loss of $1.7M ($0.25/sh) for quarter ended June 30, 2025, unchanged from $1.7M ($0.52/sh) YoY.","Operating expenses flat at $1.9M; R&D $0.9M, G&A $1.0M.","Cash and cash equivalents $12.4M, working capital $12.1M at June 30, 2025.","EB06 Phase 2 vitiligo IND data submission to FDA planned by end of calendar 2025; manufacturing activities ongoing.","EB05 program benefits from fully funded U.S. government platform study; first randomizations completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005235","json":"https://secwatch.observer/filing/0001171843-25-005235.json","markdown":"https://secwatch.observer/filing/0001171843-25-005235.md","text":"https://secwatch.observer/filing/0001171843-25-005235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325005235/0001171843-25-005235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325005235/f8k_080825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:29:28.887230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}